Anthem Biosciences Reports Q3FY26 Results with Board Approves ESOP Allotment
Anthem Biosciences announced Q3FY26 results showing revenue decline to ₹4,232 Mn but improved EBITDA margins at 41.8%. The Board approved ESOP allotment of 1,03,800 shares and recorded exceptional items of ₹254 Mn related to new Labour Code provisions. Nine-month performance remained strong with 11.2% revenue growth and 22.6% EBITDA growth.
*this image is generated using AI for illustrative purposes only.
Anthem Biosciences Limited has announced its unaudited consolidated financial results for Q3FY26 and nine months ended December 31, 2025, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors approved the financial results at their meeting held on February 05, 2026, along with significant corporate actions including ESOP allotments.
Q3FY26 Financial Performance
The company reported consolidated revenue from operations of ₹4,232 Mn for Q3FY26, compared to ₹4,978 Mn in Q3FY25, representing a 15.0% year-on-year decline. The quarterly net profit stood at ₹928 Mn with PAT margins at 20.3%, down from ₹1,243 Mn in the corresponding quarter last year. EBITDA for the quarter was ₹1,907 Mn at 41.8% margins, showing improvement from 35.2% in Q3FY25.
| Financial Metric: | Q3FY26 | Q3FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations: | ₹4,232 Mn | ₹4,978 Mn | (15.0%) |
| EBITDA: | ₹1,907 Mn | ₹1,839 Mn | 3.7% |
| EBITDA Margin: | 41.8% | 35.2% | - |
| Profit After Tax: | ₹928 Mn | ₹1,243 Mn | (25.3%) |
| PAT Margin: | 20.3% | 23.8% | - |
Board Meeting Outcomes and ESOP Allotment
The Board of Directors meeting held on February 05, 2026, which commenced at 11:40 a.m. and concluded at 12:55 p.m., approved the allotment of 1,03,800 equity shares of face value Rs. 2 each to eligible employees under the Anthem Employee Stock Option Plan 2024. The exercise price per share was Rs. 100.75 with a premium of Rs. 98.75.
| ESOP Allotment Details: | Information |
|---|---|
| Number of Shares Allotted: | 1,03,800 |
| Face Value per Share: | Rs. 2 |
| Exercise Price: | Rs. 100.75 |
| Premium per Share: | Rs. 98.75 |
| Total Shares Outstanding: | 56,17,13,851 |
| New Paid-up Capital: | Rs. 1,12,34,27,702 |
Business Segment Performance
The CRDMO business segment delivered ₹3,332 Mn in revenues for Q3FY26, declining 19.4% from ₹4,135 Mn in Q3FY25. The Specialty Ingredients segment showed positive growth with revenues of ₹899 Mn, up 6.7% from ₹843 Mn in the previous year's quarter. Other income increased significantly by 37.3% to ₹335 Mn compared to ₹244 Mn in Q3FY25.
| Segment Performance: | Q3FY26 | Q3FY25 | YoY Change |
|---|---|---|---|
| CRDMO: | ₹3,332 Mn | ₹4,135 Mn | (19.4%) |
| Specialty Ingredients: | ₹899 Mn | ₹843 Mn | 6.7% |
| Other Income: | ₹335 Mn | ₹244 Mn | 37.3% |
Nine-Month Performance Highlights
For the nine months ended December 31, 2025, Anthem Biosciences demonstrated strong overall performance with consolidated revenue from operations of ₹15,134 Mn, marking an 11.2% increase from ₹13,614 Mn in 9MFY25. EBITDA for 9MFY26 was ₹6,712 Mn at 41.5% margins, representing a 22.6% growth from the previous period.
| 9MFY26 Metrics: | Current Period | Previous Period | Growth |
|---|---|---|---|
| Revenue from Operations: | ₹15,134 Mn | ₹13,614 Mn | 11.2% |
| EBITDA: | ₹6,712 Mn | ₹5,473 Mn | 22.6% |
| EBITDA Margin: | 41.5% | 38.2% | - |
| Profit After Tax: | ₹4,020 Mn | ₹3,686 Mn | 9.1% |
| PAT Margin: | 24.8% | 25.7% | - |
Exceptional Items and Labour Code Impact
The company recorded an exceptional item of ₹254 Mn in Q3FY26 related to the new Labour Code implementation. Following the Government of India's notification of four new Labour Codes on November 21, 2025, Anthem Biosciences made provisions as recommended by the Institute of Chartered Accountants of India. The profit before tax after exceptional items was ₹1,305 Mn for the quarter.
Regulatory Filing and Financial Position
Pursuant to SEBI regulations, the company has filed its press release on unaudited consolidated financial results with BSE Limited and National Stock Exchange of India Limited. The results are also available on the company's website at www.anthembio.com/investors/ . As of December 31, 2025, the company maintains a strong net cash position of ₹12,312 Mn.
| Key Details: | Information |
|---|---|
| BSE Scrip Code: | 544449 |
| Filing Date: | February 05, 2026 |
| Net Cash Position: | ₹12,312 Mn |
| ISIN Number: | INE0CZ201020 |
Historical Stock Returns for Anthem Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.82% | +10.13% | +0.63% | -11.38% | -10.60% | -10.60% |
18
